LogoFDA 510(k) Search
Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K072965
    Device Name
    DIMENSION VISTA C1 IN; FLEX REAGENT CARTRIDGE, CAL, CON
    Manufacturer
    DADE BEHRING, INC.
    Date Cleared
    2007-12-21

    (60 days)

    Product Code
    DBA,JIT,JJX
    Regulation Number
    866.5250
    Type
    Traditional
    Panel
    Immunology
    Reference & Predicate Devices
    K960257,K962410,K962407
    Why did this record match?
    Device Name :

    DIMENSION VISTA C1 IN; FLEX REAGENT CARTRIDGE, CAL, CON

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Dimension Vista® C1IN Flex® reagent cartridge: The C1IN method is an in vitro diagnostic test for the quantitative measurement of C1 inhibitor in human serum and plasma on the Dimension Vista® System. Measurements of C1 Inhibitor aid in the diagnosis of hereditary angioneurotic edema (increase blood vessel permeability causing swelling of tissues) and a rare form of angioedema associated with lymphoma (lymph node cancer).

    Dimension Vista® C1IN CAL: The C1IN CAL is an in vitro diagnostic product for the calibration of the C1 Inhibitor (C1IN) method on the Dimension Vista® System.

    Dimension Vista® C1IN CON: C1 Inhibitor Control is an assayed, mid level, intralaboratory quality control for assessment of precision and analytical bias on the Dimension Vista® System in the quantitative determination of C1 Inhibitor (C1IN).

    Device Description

    Dimension Vista® C1IN Flex® reagent cartridge: Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a standard of known concentration.

    Dimension Vista® C1IN CAL: C1 Calibrator is a lyophilized, human plasma based product containing C1 Inhibitor (C1IN).

    Dimension Vista® C1IN CON: C1 Control is a lyophilized, mid-level, human plasma based products containing C1 Inhibitor (C1IN).

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study that proves the device meets them, based on the provided text:

    1. Table of Acceptance Criteria and Reported Device Performance

    Acceptance CriteriaReported Device Performance (Method Comparison Study)
    CorrelationCorrelation Coefficient: 0.993 (indicating very strong linear correlation)
    SlopeSlope of Regression: 0.915 (ideally close to 1 for perfect agreement)
    InterceptIntercept of Regression: 0.006 g/L (ideally close to 0 for no systematic bias)
    EquivalenceThe study "demonstrates correlation and equivalent performance" between the new and predicate devices.

    2. Sample Size Used for the Test Set and Data Provenance

    • Sample Size: 196 (serum and plasma samples)
    • Data Provenance: The text does not explicitly state the country of origin or whether the data was retrospective or prospective. It only mentions "human serum and plasma samples."

    3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

    The document does not describe the use of experts to establish a "ground truth" for the test set in the conventional sense of clinical interpretation. This is a comparison study between two assays, not a diagnostic study where human readers are making interpretations.

    4. Adjudication Method for the Test Set

    Not applicable. As noted above, this study compares the performance of two analytical assays, not diagnostic interpretations requiring adjudication.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    No, an MRMC comparative effectiveness study was not done. This study is an analytical method comparison between a new device (Dimension Vista® C1IN assay) and a legally marketed predicate device (Dade Behring N Antisera to Human C1 Inhibitor assay) on two different laboratory platforms. It does not involve human readers evaluating cases or the effect of AI assistance.

    6. Standalone Performance Study

    Yes, a standalone study was done in the sense that the performance of the Dimension Vista® C1IN assay was evaluated on its own by comparing its results to results from a predicate device. This is a common approach for demonstrating substantial equivalence for in vitro diagnostic devices. It's not "algorithm only" in the context of AI, but "device only" performance in the context of analytical measurement.

    7. Type of Ground Truth Used

    The "ground truth" in this context is the results obtained from the legally marketed predicate device, the Dade Behring N Antisera to Human C1 Inhibitor assay on the BN ProSpec® System. The study aims to show that the new device produces results that are comparable or equivalent to the established method.

    8. Sample Size for the Training Set

    Not applicable. This is an in vitro diagnostic assay, not an AI/ML device that requires a training set in the machine learning sense. The "training" for such a device typically involves method development and optimization, but not with a distinct "training set" of patient data as understood in AI.

    9. How the Ground Truth for the Training Set Was Established

    Not applicable. See point 8.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1